1PODD Stock Overview

Develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. More details

1PODD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 10.71% per year

Earnings grew by 71.9% over the past year

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Insulet Corporation Competitors

DiaSorin

BIT:DIA

€5.2b

EL.En

BIT:ELN

€767.6m

Amplifon

BIT:AMP

€4.3b

STERIS

NYSE:STE

US$22.2b

Price History & Performance

Summary of share price highs, lows and changes for Insulet
Historical stock prices
Current Share Price	US$284.00
52 Week High	US$286.90
52 Week Low	US$286.90
Beta	1.27
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	25.22%

Recent updates

Shareholder Returns

	1PODD	IT Medical Equipment	IT Market
7D	24.5%	-2.8%	3.1%
1Y	n/a	-6.2%	13.6%

Return vs Industry: Insufficient data to determine how 1PODD performed against the Italian Medical Equipment industry.

Return vs Market: Insufficient data to determine how 1PODD performed against the Italian Market.

Price Volatility

Is 1PODD's price volatile compared to industry and market?
1PODD volatility
1PODD Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.9%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1PODD's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1PODD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	3,900	Ashley McEvoy	www.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.

Insulet Corporation Fundamentals Summary

How do Insulet's earnings and revenue compare to its market cap?
1PODD fundamental statistics
Market cap	€19.71b
Earnings (TTM)	€362.62m
Revenue (TTM)	€1.98b

55.4x

P/E Ratio

10.1x

P/S Ratio

Is 1PODD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1PODD income statement (TTM)
Revenue	US$2.20b
Cost of Revenue	US$651.00m
Gross Profit	US$1.55b
Other Expenses	US$1.15b
Earnings	US$402.20m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	5.72
Gross Margin	70.39%
Net Profit Margin	18.29%
Debt/Equity Ratio	127.4%

How did 1PODD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/12 11:11
End of Day Share Price	2025/05/12 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insulet Corporation is covered by 59 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Anand Vankawala	Avondale Partners
null null	Baird
Jeffrey Johnson	Baird

Insulet BIT:1PODD Stock Report